Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

hich speak only as of their dates. These forward- looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facility; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in t
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/20/2014)... , Aug. 20, 2014 Clintrax ... services located in Raleigh, NC ... Evans as Vice President of Administration. ... will oversee all corporate processes, including their alignment ... Clintrax Global, Brad worked as an HR executive, ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... JOSE, Calif. , Aug. 20, 2014 /PRNewswire-iReach/ ... highlights the transformative collaboration between the school,s bioengineering ... As part of the Intel® Software Academic Program, ... computer sciences and the human body.  ... The study exhibits the work of Dr. ...
Breaking Biology Technology:Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Clintrax Global, Inc. Announces Addition to Executive Team 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2
... Madison Wis - The University of Wisconsin Medical ... integration of the Medical Foundation's clinical data and to ... The foundation has choosen QDX Platform V Integration ... vertical solutions company based in Englewood, Colorado. , ,The ...
... an ATM and point-of-sale (POS) processing business, said ... increase more than 57% in 2003 to 223 million ... was tremendous and makes ACCEL/Exchange one of the nation's ... President of Products and Networks for Fiserv EFT/CNS. "In ...
... Madison, Wis. -- OpGen, Inc. , a provider of ... optical mapping study of a deadly type of brain tumor, ... the Hermelin Brain Tumor Center and professor of ... founder of OpGen, David Schwartz . , ,Optical mapping, ...
Cached Biology Technology:UW Medical Foundation Integrates Medical Records 2OpGen joins UW, Henry Ford Heath in Improving Brain Tumor Treatment 2
(Date:8/20/2014)... salty aroma of sunscreen and seawater signals a relaxing ... that the idyllic beach vacation comes with an environmental ... into the sea, they can become toxic to some ... course for many other marine animals. Their study appears ... . , Antonio Tovar-Sanchez and David Snchez-Quiles point out ...
(Date:8/20/2014)... gene therapy developed by researchers at the University of ... mice from a life-threatening heart condition caused by muscular ... said Yi Lai, Ph.D., the leading author of the ... of Medicine,s Department of Molecular Microbiology and Immunology. "This ... could lead to a treatment for people with this ...
(Date:8/20/2014)... , Aug. 20, 2014  The second annual ... in Tampa, Florida on ... with Steven Rahman, Director, Technology and Strategy at Samsung, ... Experian. The theme of this year,s event is ... "Biometrics UnPlugged: Mobility at the ...
Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... soil samples indicates that a group of microorganisms called ... oxidize ammonia, according to an international team of researchers ... , Soil microbes, in a process ... nitrates, which are used as nutrients by plants. , ...
... the sequencing of the chimpanzee genome last year, geneticists have ... our closest evolutionary relative, looking for the differences that distinguish ... the human DNA sequence with the most dramatically increased rate ... is still unknown, but it appears to be directly involved ...
... estimates, hepatitis has become a worldwide health problem, ... abroad. Researchers are experimenting with combinations of ... In research presented today at Digestive Disease ... making significant progress to improve symptoms of the ...
Cached Biology News:Ammonia-loving archaea win landslide majority 2Ammonia-loving archaea win landslide majority 3Researchers identify human DNA on the fast track 2Researchers identify human DNA on the fast track 3Novel therapy combinations gain ground in treating hepatitis 2Novel therapy combinations gain ground in treating hepatitis 3Novel therapy combinations gain ground in treating hepatitis 4Novel therapy combinations gain ground in treating hepatitis 5Novel therapy combinations gain ground in treating hepatitis 6
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
...
... Anti-Clusterin α chain (human), clone 41D ... Immunogen : Native clusterin purified ... pH 7.4, 0.15M NaCl and 0.05% ... on RIPA lysates from HeLa cells ...
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Biology Products: